{
    "Trade/Device Name(s)": [
        "ONLINE TDM N-acetylprocainamide"
    ],
    "Submitter Information": "Roche Diagnostics Corporation",
    "510(k) Number": "K060738",
    "Predicate Device Reference 510(k) Number(s)": [
        "K951595"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LAN"
    ],
    "Summary Letter Date": "August 16, 2006",
    "Summary Letter Received Date": "July 24, 2006",
    "Submission Date": "July 20, 2006",
    "Regulation Number(s)": [
        "21 CFR 862.3320"
    ],
    "Regulation Name(s)": [
        "Digoxin test system"
    ],
    "Analyte Class(es)": [
        "tdm",
        "chemistry",
        "toxicology"
    ],
    "Analyte(s)": [
        "N-acetylprocainamide"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Roche Hitachi 911",
        "Roche Hitachi 912",
        "Roche Hitachi 917",
        "Roche Modular P"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay",
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Competitive binding assay",
        "Spectrophotometric detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent kit"
    ],
    "Document Summary": "FDA 510(k) summary for Roche ONLINE TDM N-acetylprocainamide homogeneous enzyme immunoassay for quantitative determination of N-acetylprocainamide in serum or plasma",
    "Indications for Use Summary": "Quantitative determination of N-acetylprocainamide in human serum or plasma to aid in diagnosis and treatment of overdose and monitoring therapeutic levels on Roche clinical chemistry analyzers",
    "fda_folder": "Toxicology"
}